Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of three single oral doses of nebicapone
(50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination
with a single-dose of controlled release levodopa 100 mg/benserazide 25 mg (Madopar® HBS
125).
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Benserazide Benserazide, levodopa drug combination Levodopa